Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,310 shares of the pharmaceutical company’s stock after selling 750 shares during the period. E. Ohman J or Asset Management AB’s holdings in Vertex Pharmaceuticals were worth $4,795,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in VRTX. Schmidt P J Investment Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 10.0% in the 3rd quarter. Schmidt P J Investment Management Inc. now owns 2,021 shares of the pharmaceutical company’s stock valued at $940,000 after acquiring an additional 183 shares during the last quarter. Dakota Wealth Management lifted its holdings in shares of Vertex Pharmaceuticals by 13.3% in the 3rd quarter. Dakota Wealth Management now owns 34,393 shares of the pharmaceutical company’s stock valued at $15,995,000 after buying an additional 4,042 shares during the period. Global Trust Asset Management LLC grew its holdings in Vertex Pharmaceuticals by 26.9% during the third quarter. Global Trust Asset Management LLC now owns 1,037 shares of the pharmaceutical company’s stock worth $482,000 after acquiring an additional 220 shares during the period. Assenagon Asset Management S.A. increased its position in Vertex Pharmaceuticals by 224.0% during the third quarter. Assenagon Asset Management S.A. now owns 311,643 shares of the pharmaceutical company’s stock worth $144,939,000 after purchasing an additional 215,448 shares during the last quarter. Finally, Bogart Wealth LLC grew its position in Vertex Pharmaceuticals by 1.2% in the third quarter. Bogart Wealth LLC now owns 19,228 shares of the pharmaceutical company’s stock worth $8,943,000 after acquiring an additional 237 shares during the period. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $471.91 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. Vertex Pharmaceuticals Incorporated has a one year low of $341.90 and a one year high of $510.64. The company’s fifty day moving average is $475.60 and its two-hundred day moving average is $461.29. The firm has a market capitalization of $121.80 billion, a P/E ratio of -232.47 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The firm had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. Vertex Pharmaceuticals’s revenue was up 6.1% compared to the same quarter last year. During the same period last year, the firm earned $3.53 EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of research analyst reports. Truist Financial reiterated a “buy” rating and set a $550.00 price target (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, October 8th. TD Cowen boosted their price target on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Bank of America decreased their target price on Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating for the company in a report on Monday, October 14th. Finally, Guggenheim upped their price target on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $492.92.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the sale, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the sale, the chief marketing officer now directly owns 23,259 shares of the company’s stock, valued at $11,088,728.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce I. Sachs sold 5,295 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,005 shares of company stock worth $5,988,066 in the last three months. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.